Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs to Present at NewsMakers in the Biotech Industry Conference
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - September 8, 2009) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that the Company is scheduled to present at the 16th Annual
NewsMakers in the Biotech Industry Conference, presented by BioCentury and
Thomson Reuters, September 16, in New York City.
Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland
BioLabs, will give a presentation on September 16, at 2:00 p.m. Eastern
Daylight Time. An audio webcast of the presentation may be accessed at the
Company's website, www.cbiolabs.com, in the Investors section. A replay of
the presentation will be archived for 90 days after the conference at the
same location. For more information on the NewsMakers in the Biotech
Industry Conference, please visit www.biocentury.com.
Cleveland BioLabs is developing a pipeline of products for multiple defense
and medical applications from two primary families of compounds: Protectans
and Curaxins. Protectans are being developed as drug candidates that
protect normal tissues from acute stresses such as radiation and
chemotherapy. Curaxins are being developed as anticancer agents that could
act as mono-therapy drugs or in combination with other existing anticancer
agents.
Cleveland BioLabs's most advanced compound, Protectan CBLB502, is a
derivative of a microbial protein, which has demonstrated the capacity to
reduce injury from acute stresses, such as radiation and chemotherapy, in
animal models. CBLB502 mobilizes several cell protective mechanisms,
including inhibition of programmed cell death (apoptosis), reduction of
oxidative damage and induction of regeneration-promoting cytokines.
CBLB502 is being developed under the U.S. Food and Drug Administration's
Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation
poisoning from any exposure to radiation such as a nuclear or radiological
weapon/ dirty bomb, or from a nuclear accident. This approval pathway
requires demonstration of efficacy in representative animal models and
safety and drug metabolism testing in healthy human volunteers.
Evidence of CBLB502's mechanism of action and activity in animal models was
published in Science Magazine in April 2008 (Science, 2008, vol. 320, pp.
226-230). Data from 50 subjects in an initial Phase I safety and
tolerability study indicated that CBLB502 was well tolerated and that
normalized biomarker results corresponded to previously demonstrated
activity in animal models of ARS. As part of the development of CBLB502,
this study will be followed by a second, larger safety study in healthy
human volunteers, which will be based on the results of the initial study.
There is currently no FDA approved medical countermeasure to treat ARS.
CBLB502 is also being developed as a supportive care measure to reduce and
prevent occurrence of side effects of radiotherapy or chemotherapy in
cancer treatment.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 30, 2009.